Accelrys and Confirmant to Co-market Annotations for Protein Atlas
Confirmant of Abingdon, UK, and Accelrys of San Diego said last week they are collaborating on a new database product. Confirmant has licensed Accelrys’ GeneAtlas annotation software and will use it to annotate the function of protein sequences contained in Protein Atlas, its database of proteins mapped onto the human genome. The result will be a new annotation database, which both companies will market as an addition to Protein Atlas. It will be contained within Accelrys’ Discovery Studio AtlasStore, an Oracle-based database that integrates protein sequence, structure, and annotation data.
U. of Florida Gets $2.2M DOD Award to Study Brain Injury Biomarkers
Scientists at the University of Florida in Gainesville have obtained a $2.17 million award from the Department of Defense’s Peer Reviewed Medical Research Program to study biomarkers related to brain injury. Researchers from the university’s McKnight Brain Institute and from the Walter Reed Army Institute of Research aim to discover protein biomarkers in cerebrospinal fluid or blood for distinguishing traumatic and ischemic brain injury. Gainesville-based Daimonion Diagnostics is planning to commercialize the technology.
Ciphergen and Biosite Collaborate On Diagnostic Biomarkers
Ciphergen Biosystems of Fremont, Calif., and Biosite of San Diego are collaborating to discover biomarkers for cardiovascular and other diseases for diagnostic tests. Ciphergen will use its ProteinChip technology to discover protein biomarkers in clinical samples provided by Biosite, and both companies plan to analyze these further for their diagnostic utility. Biosite then wants to develop antibodies against these markers.
Either company will receive royalties from products the other one develops and commercializes. Other terms of the agreement were not disclosed.
SurroMed Receives Funding from Fidelity Biosciences to Develop Biomarkers
SurroMed of Mountain View, Calif., will receive an undisclosed amount of multi-year funding from Fidelity Biosciences Group, based in Boston, to develop biomarkers for neurodegenerative diseases and to conduct preclinical and clinical studies. SurroMed will analyze preclinical and clinical samples and will share in the commercialization of biomarkers resulting from these studies.
Fidelity Biosciences is a division of Fidelity Investments that invests private equity in the biosciences industry.